Literature DB >> 26391778

Cancer-treatment-induced neurotoxicity--focus on newer treatments.

Jacqueline B Stone1, Lisa M DeAngelis1.   

Abstract

Neurotoxicity caused by traditional chemotherapy and radiotherapy is widely recognized in patients with cancer. The adverse effects of newer therapeutics, such as biological and immunotherapeutic agents, are less well established, and are associated with considerable neurotoxicity in the central and peripheral nervous systems. This Review addresses the main neurotoxicities of cancer treatment with a focus on the newer therapeutics. Recognition of these patterns of toxicity is important because drug discontinuation or dose adjustment might prevent further neurological injury. Knowledge of these toxicities also helps to differentiate treatment-related symptoms from progression of cancer or its involvement of the nervous system. Familiarity with the neurological syndromes associated with cancer treatments enables clinicians to use the appropriate treatment for the underlying malignancy while minimizing the risk of neurological damage, which might preserve patients' quality of life.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26391778      PMCID: PMC4979320          DOI: 10.1038/nrclinonc.2015.152

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  71 in total

1.  Radiation-induced brachial plexopathy: MR and clinical findings.

Authors:  B C Bowen; A Verma; A H Brandon; J A Fiedler
Journal:  AJNR Am J Neuroradiol       Date:  1996 Nov-Dec       Impact factor: 3.825

2.  Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring.

Authors:  Linda Mileshkin; Richard Stark; Bruce Day; John F Seymour; Jerome B Zeldis; H Miles Prince
Journal:  J Clin Oncol       Date:  2006-08-28       Impact factor: 44.544

Review 3.  Mechanisms and functional implications of adult neurogenesis.

Authors:  Chunmei Zhao; Wei Deng; Fred H Gage
Journal:  Cell       Date:  2008-02-22       Impact factor: 41.582

Review 4.  Review article: metoclopramide and tardive dyskinesia.

Authors:  A S Rao; M Camilleri
Journal:  Aliment Pharmacol Ther       Date:  2010-01       Impact factor: 8.171

Review 5.  Peripheral neuropathy induced by microtubule-stabilizing agents.

Authors:  James J Lee; Sandra M Swain
Journal:  J Clin Oncol       Date:  2006-04-01       Impact factor: 44.544

6.  Chemotherapy-induced neuropathy.

Authors:  Guido Cavaletti; Paola Alberti; Barbara Frigeni; Marialuisa Piatti; Emanuela Susani
Journal:  Curr Treat Options Neurol       Date:  2011-04       Impact factor: 3.598

Review 7.  The double-edged sword: Neurotoxicity of chemotherapy.

Authors:  Rajiv S Magge; Lisa M DeAngelis
Journal:  Blood Rev       Date:  2014-09-28       Impact factor: 8.250

Review 8.  Radiation necrosis: relevance with respect to treatment of primary and secondary brain tumors.

Authors:  James Fink; Donald Born; Marc C Chamberlain
Journal:  Curr Neurol Neurosci Rep       Date:  2012-06       Impact factor: 5.081

9.  Neurological immune-related adverse events of ipilimumab.

Authors:  Ilja Bot; Christian U Blank; Willem Boogerd; Dieta Brandsma
Journal:  Pract Neurol       Date:  2013-03-13

10.  Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiation as CNS treatment in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute ALL Consortium Protocol 95-01.

Authors:  Deborah P Waber; Jennifer Turek; Lori Catania; Kristen Stevenson; Philippe Robaey; Ivonne Romero; Heather Adams; Cheryl Alyman; Christine Jandet-Brunet; Donna S Neuberg; Stephen E Sallan; Lewis B Silverman
Journal:  J Clin Oncol       Date:  2007-11-01       Impact factor: 44.544

View more
  50 in total

1.  Combination of Blinatumomab and Vincristine Sulfate Liposome Injection for Treatment of Relapsed Philadelphia Chromosome Positive B-cell Acute Lymphoblastic Leukemia.

Authors:  Michael G McCusker; Firas El Chaer; Alison Duffy; Ashkan Emadi; Vu H Duong
Journal:  Am J Leuk Res       Date:  2018-03-23

Review 2.  Late effects of cancer treatment: consequences for long-term brain cancer survivors.

Authors:  Montse Alemany; Roser Velasco; Marta Simó; Jordi Bruna
Journal:  Neurooncol Pract       Date:  2020-07-16

3.  Successful treatment of cytarabine-related neurotoxicity with corticosteroids, a case series.

Authors:  Jennifer L Dotson; Muhammad Omer Jamil
Journal:  Int J Hematol       Date:  2018-06-26       Impact factor: 2.490

4.  Correction regarding data on blinatumomab-associated seizures.

Authors:  Max S Topp; Zachary Zimmerman; Hagop M Kantarjian
Journal:  Nat Rev Clin Oncol       Date:  2016-08-23       Impact factor: 66.675

5.  Correction regarding data on blinatumomab-associated seizures.

Authors:  Jacqueline B Stone; Lisa M DeAngelis
Journal:  Nat Rev Clin Oncol       Date:  2016-08-23       Impact factor: 66.675

6.  Identification and Characterization of New Chemical Entities Targeting Apurinic/Apyrimidinic Endonuclease 1 for the Prevention of Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Mark R Kelley; James H Wikel; Chunlu Guo; Karen E Pollok; Barbara J Bailey; Randy Wireman; Melissa L Fishel; Michael R Vasko
Journal:  J Pharmacol Exp Ther       Date:  2016-09-08       Impact factor: 4.030

7.  Mesenchymal stem cells confer resistance to doxorubicin-induced cardiac senescence by inhibiting microRNA-34a.

Authors:  Wenzheng Xia; Meng Hou
Journal:  Oncol Lett       Date:  2018-04-23       Impact factor: 2.967

Review 8.  Evaluation and management of chimeric antigen receptor (CAR) T-cell-associated neurotoxicity.

Authors:  Luis Nicolas Gonzalez Castro; Jorg Dietrich
Journal:  Neurooncol Pract       Date:  2020-11-29

9.  Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity.

Authors:  Fernando Souza-Fonseca-Guimaraes; Stephen J Blake; Amani Makkouk; Cariad Chester; Holbrook E Kohrt; Mark J Smyth
Journal:  Oncoimmunology       Date:  2016-06-30       Impact factor: 8.110

Review 10.  The confused oncologic patient: a rational clinical approach.

Authors:  Craig Nolan; Lisa M DeAngelis
Journal:  Curr Opin Neurol       Date:  2016-12       Impact factor: 5.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.